





Abstract

Every year, 650,000 new cancer patients are treated with chemotherapy. As a side effect, their neutrophils, the most common white cells fighting infection, fall to low levels. The severity and prolonging of this state, called neutropenia, significantly increases the risk of infection episodes, called febrile neutropenia (FN), which entail costly hospitalization and even death. Current technologies for neutropenia testing require blood draws at healthcare centers and thus happen too infrequently. We aim to overcome this limitation with the first noninvasive screening device that can be used routinely in local health centers or at home for the early detection of severe neutropenia before FN occurs.

Problem statement





hospitalization costs

MDAnderson **Cancer** Center

Non-invasive white cells Leuko Labs Inc.

Status of solution



Our idea: Estimating neutropenia noninvasively with a portable optical device



Images taken from videos of the capillaries show red blood cells (dark areas in the vessel due to light

Contact us! contact@leuko.com www.leuko.com